In a report released today, Matthew Sykes from Goldman Sachs downgraded Cue Health (HLTH – Research Report) to a Hold, with a price target of $2.00. The company’s shares closed yesterday at $0.71.
Sykes covers the Healthcare sector, focusing on stocks such as Cue Health, Myriad Genetics, and LumiraDx. According to TipRanks, Sykes has an average return of -14.6% and a 31.43% success rate on recommended stocks.
Currently, the analyst consensus on Cue Health is a Moderate Buy with an average price target of $4.75.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $5.47 and a one-year low of $0.61. Currently, Cue Health has an average volume of 423.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cue Health Inc is a health technology company. It puts consumers in control of health information and places diagnostic information at the center of care. It enables people to manage health through real-time, actionable and connected health data. Further, it offers individuals, enterprises, government agencies and healthcare providers access to lab-quality diagnostic testing at home, at work, or at the point-of-care, all in a device that fits in the palm of hand.
